Mycobacterium tuberculosis: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Alex Lee
(New page: == '''Eduzendium - a Citizendium initiative''' == This article is currently being developed as part of the Eduzendium initiative. It is a student project involving the General Microb...)
 
mNo edit summary
 
(60 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{subpages}}
{{Taxobox
| color = pink
| name = 
| image = TB_Culture.jpg|thumb
| regnum = Bacteria
| phylum = Actinobacteria
| classis = Actinomycetales
| ordo =  Corynebacterineae
| familia = Mycobacteriaceae
| genus =  Mycobacterium
| species = tuberculosis
| binomial = ''Mycobacterium tuberculosis''
| binomial_authority = 
}}
==Description and significance==
Mycobacterium tuberculosis was first isolated and described in 1882 by Dr. [[Robert Koch]], who later went on to win the [[Nobel Prize]] in 1905 for his discovery. Also known as, "Tubercle Bacillus", and Koch's bacillus, M. Tuberculosis is a non-motile, rod shaped bacterium, and the primary cause for the widespread disease [[tuberculosis]].


== '''[[Eduzendium]] - a Citizendium initiative''' ==
The [[World Health Organization]] estimates that one-third of the world's population is infected with M. Tuberculosis, and that someone new is infected every second. <ref>http://www.who.int/mediacentre/factsheets/fs104/en/index.html</ref> With the emergence of drug resistant strains, both multi drug resistant (MDR) and extensively drug resistant (XDR), controlling the spread of tuberculosis has become a major concern. Since 2006, the WHO's primary strategy in its Stop TB Strategy has been the use of [[DOTS]] ([[Directly Observed Treatment]], Short-course). It is estimated to be the most cost effective strategy, only costing $3-$7 to gain a year of health. <ref>http://www.tbalert.org/worldwide/DOTS.php</ref>


This article is currently being developed as part of the Eduzendium initiative. It is a student project involving the General Microbiology course at Queens College in New York City. As such, it is closed to outside editing for the duration of the course.
==Genome structure==
 
The genome for two strains of M. Tuberculosis have been sequenced completely. In 1998, the [[Sanger Institute]] sequenced the common laboratory strain, H37rv. At the same time, strain CD1551 was sequenced by [[The Institute for Genomic Research]] ([[TIGR]]) using the [[whole genome random sequencing method]] ([[shotgun sequencing]]). The CDC-1551 strain has been shown to be more virulent than the H37rv strain. By comparing both genomes, key information can be obtained about the virulence, survivability (drug resistance), and evolution of M. Tuberculosis<ref>http://cmr.tigr.org/CMR/org_gmt.shtml</ref><ref>http://www.biohealthbase.org/GSearch/aboutMycobacterium.do?decorator=Mycobacterium</ref>
The anticipated date of course completion is 1st May 2008. At the end of the project period, this notice will be removed and the article reopened to general editing.
 
Thank you.
 
==Classification==
 
[[Image: Tosco_Refinery.jpg]]
 
===Higher order taxa===
 
Domain; Phylum; Class; Order; family [Others may be usedUse [http://www.tolweb.org/tree/ Tree of Life] link to find]
 
===Species===
 
''Genus species''[[Image:Example.jpg]]


==Description and significance==
Chart from [http://cmr.jcvi.org/tigr-scripts/CMR/GenomePage.cgi?database=gmt "TIGR"]summarizing the CDC-1551 strain
Describe the appearance, habitat, etc. of the organism, and why it is important enough to have its genome sequencedDescribe how and where it was isolated.
{| class="wikitable"
Include a picture or two (with sources) if you can find them.
|-
|DNA Molecule Summary
|-
|Total Number of all DNA molecules:
|1
|100.00%
|-
|Total Size of all DNA molecules:
|4403837 bp
|100.00%
|-
|Number of Primary Annotation coding bases:
|4069477 bp
|92.40%
|-  
|Number of G+C bases:
|2889216 bp
|65.60%
|-
|-
|}


==Genome structure==
{| class="wikitable"
Describe the size and content of the genomeHow many chromosomes? Circular or linear?  Other interesting features?  What is known about its sequence?
|-
Does it have any plasmids?  Are they important to the organism's lifestyle?
|Primary Annotation Summary
|-
|Total genes:
|4294
|100.00%
|-  
|Protein coding genes:
|4246
|98.88%
|-   
|Genes assigned a role category:
|2317
|54.56%
|- 
|Genes not assigned a role category:
|2
|0.04%
|- 
|Conserved hypothetical genes:
|655
|15.42%
|-  
|Hypothetical genes:
|1272
|29.95%
|- 
|tRNA genes:
|45
|1.04%
|- 
|rRNA genes:
|3
|0.06%
|}


==Cell structure and metabolism==
==Cell structure and metabolism==
Describe any interesting features and/or cell structures; how it gains energy; what important molecules it produces.
[[Image:AFBpubdomaincdc.jpg|300 px|thumb|left|M. Tuberculosis: Ziehl-Neelsan Stain]]
M. Tuberculosis is a non-motile, rod shaped bacterium roughly 2-4 um in length and 0.2-0.5 um in width. It's an [[obligate aerobe]] and neither Gram-positive or Gram-negative. Although it has a peptidoglycan layer, M. Tuberculosis does not retain the crystal violet dye. To solve this issue, [[acid-fast stain]]ing is used (specifically [[Ziehl-Neelsan Stain]]). The peptidoglycan layer is of particular interest. It is composed mostly of lipids (60%). The high [[lipid]] percentage (lipids: Mycolic Acid, Cord Factor, Wax-D) is the likely cause of the high survivability of M. Tuberculosis. Factors include: impermeability to stains; resistance to [[antibiotics]], [[osmotic lysis]], [[acidic]] and [[alkaline]] compounds, and protection from oxygen [[free radicals]]. other factors that add to the survivability of M. Tuberculosis include the ability to grow intracellularly within macrophages (exact reason is unknown), and it's slow rate of growth compared to other [[bacteria]] (about 15-20 hours). The slow rate of growth may deter it's detection by the immune system.<ref>http://www.textbookofbacteriology.net/tuberculosis.html</ref>


==Ecology==
==Ecology==
Describe any interactions with other organisms (included eukaryotes), contributions to the environment, effect on environment, etc.
[[Image:TBXray2543.jpg |300 px|thumb|right|Chest X-ray of lungs showing M. Tuberculosis]]
M. Tuberculosis generally resides in the lungs where oxygen is more readily available. However, if the bacteria enters the blood stream, or [[lymphatic system]], it can spread throughout the body and infect various other organs (brain, kidney, liver, etc.) When this happens, it is known as [[miliary tuberculosis]].
 
M. Tuberculosis has an increased capability to survive outside our system due to its highly lipid based peptidoglycan layer. Within our system,  M. Tuberculosis are consumed by macrophages, however lysosome-phagosome fusion is prevented, and M. TB is able to grow inside the macrophages.<ref>http://www.biohealthbase.org/GSearch/aboutMycobacterium.do?decorator=Mycobacterium</ref><ref>http://www.textbookofbacteriology.net/tuberculosis.html</ref>


==Pathology==
==Pathology==
How does this organism cause disease?  Human, animal, plant hosts?  Virulence factors, as well as patient symptoms.
M. Tuberculosis is the major cause of tuberculosis. Transmission of M. TB is by means of droplet nuclei which contain the bacteria. Coughing (a common symptom of tuberculosis), talking, singing, and definitely sneezing are methods of transmission. Due to the small size of the droplets, they are able to linger in the air for an extended amount of time. After inhalation of the bacteria, it will make its way to your lungs, where [[macrophages]] will consume them. However, M. Tuberculosis prevents [[lysome]]-[[phagosome]] fusion and as a result is not destroyed. Continually growing in the macrophages, a cell mediated immune response will occur. The body will attempt to quarantine the bacteria (use of macrophages and [[T cells]]), as a result, Tuberculosis nodules are formed, or more generally [[granulomas]]. However, due to the increased survivability, and persistence of M. TB, in some cases it may be able to continue to grow. Eventually spreading from the [[alveoli]] to the [[bronchi]] and then throughout the lungs. In rare cases, M. tuberculosis may be able to enter the blood stream, or [[lymphatic system]]s, the resulting disease is know as Miliary Tuberculosis. Miliary Tuberculosis is estimated to only occur in 1.5% of all TB patients. <ref>http://www.emedicine.com/med/TOPIC1476.HTM</ref>


==Application to Biotechnology==
==Current Research==
Does this organism produce any useful compounds or enzymes? What are they and how are they used?
Currently the only vaccine for tuberculosis is the bacille Calmette-Guerin (BCG) vaccine which comes from an attenuated strand of mycobacterium bovis. The BCG vaccine is not used widely in many countries, including the United States, due to the fact that it causes a false positive result with the tuberculin skin test (TST), or sometimes simply known as a PPD (purified protein derivative). There has been research ongoing that has discovered that two proteins, namely narK2 (Rv1737c) and narX (Rv1736c), may be used to differentiate between the BCG vaccine, and latent tuberculosis. <ref>http://www.ncbi.nlm.nih.gov/pubmed/18362135?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum|</ref>


==Current Research==
Other vaccines are undergoing clinical trials, and one of the main reasons allowing this to happen is the complete sequencing of the genome. With the genome sequenced, it is possible for researches to study enzymes that they previously could not due to the fact that the expression of the enzyme was low. One such case is the study of lipolytic enzymes that degrade internal and external lipids. The research team theorizes that this lipolytic enzyme may be correlated to the virulence of mycobacterium tuberculosis. <ref>http://www.ncbi.nlm.nih.gov/pubmed/18309478?ordinalpos=19&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum|</ref>


Enter summaries of the most recent research here--at least three required
As often preached, prevention is one of the keys to controlling a disease. Obviously however, treatment for those diseased are vital as well. Although there are numerous ways to treat M. tuberculosis, there has been a surge in strains that are resistant to our current drugs. Both multi-drug resistance, and extensively drug resistance is on the rise worldwide. By understanding the phenotypical/genotypical differences between strains with resistance and those without, it may be possible to control the surge of drug resistant strains. <ref>http://jac.oxfordjournals.org/cgi/content/full/59/5/866</ref>


==References==
==References==
[Sample reference] [http://ijs.sgmjournals.org/cgi/reprint/50/2/489 Takai, K., Sugai, A., Itoh, T., and Horikoshi, K. "''Palaeococcus ferrophilus'' gen. nov., sp. nov., a barophilic, hyperthermophilic archaeon from a deep-sea hydrothermal vent chimney". ''International Journal of Systematic and Evolutionary Microbiology''. 2000. Volume 50. p. 489-500.]
{{reflist|2}}[[Category:Suggestion Bot Tag]]
 
[http://en.citizendium.org/wiki/Main_Page | Citizendium]

Latest revision as of 06:01, 22 September 2024

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
TB Culture.jpg
Scientific classification
Kingdom: Bacteria
Phylum: Actinobacteria
Class: Actinomycetales
Order: Corynebacterineae
Family: Mycobacteriaceae
Genus: Mycobacterium
Species: tuberculosis
Binomial name
Mycobacterium tuberculosis

Description and significance

Mycobacterium tuberculosis was first isolated and described in 1882 by Dr. Robert Koch, who later went on to win the Nobel Prize in 1905 for his discovery. Also known as, "Tubercle Bacillus", and Koch's bacillus, M. Tuberculosis is a non-motile, rod shaped bacterium, and the primary cause for the widespread disease tuberculosis.

The World Health Organization estimates that one-third of the world's population is infected with M. Tuberculosis, and that someone new is infected every second. [1] With the emergence of drug resistant strains, both multi drug resistant (MDR) and extensively drug resistant (XDR), controlling the spread of tuberculosis has become a major concern. Since 2006, the WHO's primary strategy in its Stop TB Strategy has been the use of DOTS (Directly Observed Treatment, Short-course). It is estimated to be the most cost effective strategy, only costing $3-$7 to gain a year of health. [2]

Genome structure

The genome for two strains of M. Tuberculosis have been sequenced completely. In 1998, the Sanger Institute sequenced the common laboratory strain, H37rv. At the same time, strain CD1551 was sequenced by The Institute for Genomic Research (TIGR) using the whole genome random sequencing method (shotgun sequencing). The CDC-1551 strain has been shown to be more virulent than the H37rv strain. By comparing both genomes, key information can be obtained about the virulence, survivability (drug resistance), and evolution of M. Tuberculosis. [3][4]

Chart from "TIGR"summarizing the CDC-1551 strain

DNA Molecule Summary
Total Number of all DNA molecules: 1 100.00%
Total Size of all DNA molecules: 4403837 bp 100.00%
Number of Primary Annotation coding bases: 4069477 bp 92.40%
Number of G+C bases: 2889216 bp 65.60%
Primary Annotation Summary
Total genes: 4294 100.00%
Protein coding genes: 4246 98.88%
Genes assigned a role category: 2317 54.56%
Genes not assigned a role category: 2 0.04%
Conserved hypothetical genes: 655 15.42%
Hypothetical genes: 1272 29.95%
tRNA genes: 45 1.04%
rRNA genes: 3 0.06%

Cell structure and metabolism

M. Tuberculosis: Ziehl-Neelsan Stain

M. Tuberculosis is a non-motile, rod shaped bacterium roughly 2-4 um in length and 0.2-0.5 um in width. It's an obligate aerobe and neither Gram-positive or Gram-negative. Although it has a peptidoglycan layer, M. Tuberculosis does not retain the crystal violet dye. To solve this issue, acid-fast staining is used (specifically Ziehl-Neelsan Stain). The peptidoglycan layer is of particular interest. It is composed mostly of lipids (60%). The high lipid percentage (lipids: Mycolic Acid, Cord Factor, Wax-D) is the likely cause of the high survivability of M. Tuberculosis. Factors include: impermeability to stains; resistance to antibiotics, osmotic lysis, acidic and alkaline compounds, and protection from oxygen free radicals. other factors that add to the survivability of M. Tuberculosis include the ability to grow intracellularly within macrophages (exact reason is unknown), and it's slow rate of growth compared to other bacteria (about 15-20 hours). The slow rate of growth may deter it's detection by the immune system.[5]

Ecology

Chest X-ray of lungs showing M. Tuberculosis

M. Tuberculosis generally resides in the lungs where oxygen is more readily available. However, if the bacteria enters the blood stream, or lymphatic system, it can spread throughout the body and infect various other organs (brain, kidney, liver, etc.) When this happens, it is known as miliary tuberculosis.

M. Tuberculosis has an increased capability to survive outside our system due to its highly lipid based peptidoglycan layer. Within our system, M. Tuberculosis are consumed by macrophages, however lysosome-phagosome fusion is prevented, and M. TB is able to grow inside the macrophages.[6][7]

Pathology

M. Tuberculosis is the major cause of tuberculosis. Transmission of M. TB is by means of droplet nuclei which contain the bacteria. Coughing (a common symptom of tuberculosis), talking, singing, and definitely sneezing are methods of transmission. Due to the small size of the droplets, they are able to linger in the air for an extended amount of time. After inhalation of the bacteria, it will make its way to your lungs, where macrophages will consume them. However, M. Tuberculosis prevents lysome-phagosome fusion and as a result is not destroyed. Continually growing in the macrophages, a cell mediated immune response will occur. The body will attempt to quarantine the bacteria (use of macrophages and T cells), as a result, Tuberculosis nodules are formed, or more generally granulomas. However, due to the increased survivability, and persistence of M. TB, in some cases it may be able to continue to grow. Eventually spreading from the alveoli to the bronchi and then throughout the lungs. In rare cases, M. tuberculosis may be able to enter the blood stream, or lymphatic systems, the resulting disease is know as Miliary Tuberculosis. Miliary Tuberculosis is estimated to only occur in 1.5% of all TB patients. [8]

Current Research

Currently the only vaccine for tuberculosis is the bacille Calmette-Guerin (BCG) vaccine which comes from an attenuated strand of mycobacterium bovis. The BCG vaccine is not used widely in many countries, including the United States, due to the fact that it causes a false positive result with the tuberculin skin test (TST), or sometimes simply known as a PPD (purified protein derivative). There has been research ongoing that has discovered that two proteins, namely narK2 (Rv1737c) and narX (Rv1736c), may be used to differentiate between the BCG vaccine, and latent tuberculosis. [9]

Other vaccines are undergoing clinical trials, and one of the main reasons allowing this to happen is the complete sequencing of the genome. With the genome sequenced, it is possible for researches to study enzymes that they previously could not due to the fact that the expression of the enzyme was low. One such case is the study of lipolytic enzymes that degrade internal and external lipids. The research team theorizes that this lipolytic enzyme may be correlated to the virulence of mycobacterium tuberculosis. [10]

As often preached, prevention is one of the keys to controlling a disease. Obviously however, treatment for those diseased are vital as well. Although there are numerous ways to treat M. tuberculosis, there has been a surge in strains that are resistant to our current drugs. Both multi-drug resistance, and extensively drug resistance is on the rise worldwide. By understanding the phenotypical/genotypical differences between strains with resistance and those without, it may be possible to control the surge of drug resistant strains. [11]

References